UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934

          For quarterly period ended September 30, 2003

[ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


          NEVADA                                          87-0458170
(State of incorporation)                 (I.R.S.  Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [  ]

As of October 28, 2003 the issuer had a total of 708,000 shares of common
stock issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]


<PAGE>

                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1:  Financial Statements.................................. 3

Item 2:  Plan of Operations ................................... 8

Item 3:  Controls and Procedures............................... 9

                    PART II: OTHER INFORMATION

Item 6:  Exhibits and Reports on Form 8-K ..................... 9

Signatures..................................................... 9




                 PART I:   FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

     The financial information set forth below with respect to our statements
of operations for the three and nine month periods ended September 30, 2003
and 2002 is unaudited.  This financial information, in the opinion of
management, includes all adjustments consisting of normal recurring entries
necessary for the fair presentation of such data.  The results of operations
for the nine month period ended September 30, 2003, are not necessarily
indicative of results to be expected for any subsequent period.



                                2




<PAGE>







             Skinovation Pharmaceutical Incorporated

                       Financial Statements

                        September 30, 2003



                                3
<PAGE>




                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                          Balance Sheets


                              ASSETS

                                                    Sept. 30,    December 31,
                                                      2003         2002
                                                 -------------- -------------
                                                  (Unaudited)
CURRENT ASSETS                                   $           -  $          -
                                                 -------------- -------------

  TOTAL ASSETS                                   $           -  $          -
                                                 ============== =============


               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                 $      33,776  $     33,776
                                                 -------------- -------------

  Total Liabilities                                     33,776        33,776
                                                 -------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000
  shares authorized; 708,000 shares issued
  and outstanding                                          708           708

Additional Paid in Capital                              25,148        25,148

Deficit Accumulated During the Development Stage       (59,632)      (59,632)
                                                 -------------- -------------

  Total Stockholders' Equity                           (33,776)      (33,776)
                                                 -------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY     $           -  $          -
                                                 ============== =============


                                4

<PAGE>
<TABLE>
<CAPTION>


                 Skinovation Pharmaceutical, Inc.
                   (Development Stage Company)
                     Statement of Operations
                           (Unaudited)




                                                                                          From
                                                                                          inception on
                              For the three  For the three  For the nine   For the nine   January 15,
                              months ended   months ended   months ended   months ended   1988 to
                              Sept. 30,      Sept. 30,      Sept. 30,      Sept. 30,      Sept. 30,
                              2003           2002           2003           2002           2003
                              -------------- -------------- -------------- -------------- ---------------

                           <c>            <c>            <c>            <c>            <c>
REVENUES                      $           -  $           -  $           -  $           -  $       27,937
                              -------------- -------------- -------------- -------------- ---------------
EXPENSES
  General & Administrative                -              -              -              -         124,644
                              -------------- -------------- -------------- -------------- ---------------

    TOTAL EXPENSES                        -              -              -              -         124,644
                              -------------- -------------- -------------- -------------- ---------------
NET LOSS BEFORE DISCONTINUED
  OPERATIONS                              -              -              -              -         (96,707)

GAIN ON DISPOSAL OF OPERATIONS            -              -              -              -          37,075
                              -------------- -------------- -------------- -------------- ---------------

NET INCOME (LOSS)             $           -  $           -  $           -  $           -  $      (59,632)
                              ============== ============== ============== ============== ===============

NET LOSS PER SHARE            $           -  $           -  $           -  $           -  $        (0.17)
                              ============== ============== ============== ============== ===============
WEIGHTED AVERAGE SHARES
  OUTSTANDING                       708,000        708,000        708,000        708,000         352,815
                              ============== ============== ============== ============== ===============


                                        5



</TABLE>
<PAGE>
<TABLE>
<CAPTION>
                        Skinovation Pharmaceutical, Inc.
                          (A Development Stage Company)
                             Statement of Cash Flows
                                   (Unaudited)

                                                                                        From
                                                                                        Inception on
                                                             For the nine months ended  January 15,
                                                                     Sept. 30,          1988 Through
                                                            --------------------------- Sept 30,
                                                                2003             2002   2003
                                                            ------------- ------------- -------------

                                                         <c>           <c>           <c>
Cash Flows from Operating Activities

  Net Loss                                                  $          -  $          -  $    (59,632)
  Less  Non-cash Items:
   Shares issued for services                                          -             -        10,433
   Shares issued for debt payment                                      -             -         1,424
   Increase in accounts payable                                        -             -        33,776
   Loss on disposal of PP&E                                            -             -         5,263
                                                            ------------- ------------- -------------

  Net Cash Provided (Used) by Operating Activities                     -             -        (8,736)
                                                            ------------- ------------- -------------
Cash Flows from Investing Activities

  Cash paid for PP&E                                                   -             -        (5,264)
                                                            ------------- ------------- -------------

  Net Cash Provided (Used) by Investing Activities                     -             -        (5,264)
                                                            ------------- ------------- -------------
Cash Flows from Financing Activities
  Cash paid for offering costs                                         -             -        (7,000)
  Common stock issued for cash                                         -             -        21,000
                                                            ------------- ------------- -------------

  Net Cash Provided (Used) by Financing Activities                     -             -        14,000
                                                            ------------- ------------- -------------

Increase (Decrease) in Cash                                            -             -             -

Cash and Cash Equivalents at Beginning of Period                       -             -             -
                                                            ------------- ------------- -------------

Cash and Cash Equivalents at End of Period                  $          -  $          -  $          -
                                                            ============= ============= =============

Supplemental Cash Flow Information:
  Stock issued for debt payment                             $          -  $          -  $      1,424
  Stock issued for services                                 $          -  $          -  $     10,433
  Cash Paid For:
    Interest                                                $          -  $          -  $          -
    Income Taxes                                            $          -  $          -  $          -


                                        6

</TABLE>
<PAGE>




             Skinovation Pharmaceutical Incorporated
                  (A Development Stage Company)
                Notes to the Financial Statements
                        September 30, 2003


GENERAL
-------

Skinovation Pharmaceutical Incorporated (the Company) has elected to omit
substantially all footnotes to the financial statements for the nine months
ended September 30, 2003 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2002.

UNAUDITED INFORMATION
---------------------

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.













                                7




<PAGE>

     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

     This Form 10-QSB contains certain forward-looking statements and any
statements contained in this Form 10-QSB that are not statements of historical
fact may be deemed to be forward-looking statements.  Without limiting the
foregoing, words such as "may," "will," "expect," "believe," "anticipate,"
"estimate" or "continue" or comparable terminology are intended to identify
forward-looking statements.  These statements by their nature involve
substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within Skinovation's
control.  These factors include, but are not limited to, economic conditions
generally, failure by management to successfully develop business
relationships, competition within the merger and acquisitions market, and our
lack of operations.

ITEM 2:  PLAN OF OPERATIONS

     We are a development stage company with no assets, we have experienced
losses since our inception and we are dependent on financing to continue our
operations.  For the nine month period ended September 30, 2003, we had no
cash on hand and total current liabilities of $33,776.  The current
liabilities reflect expenses related to our reporting obligations under the
Exchange Act.  We have incurred these expenses for preparation of our reports
and the costs of filing the reports with the SEC.  In the event we acquire a
business opportunity we may incur additional reporting expenses related to
proxy or information statements we may be required to provide to our
stockholders which disclose the company to be acquired's business operations,
management and financial condition.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  However,
these understandings are not formal agreements and therefore these persons are
not obligated to provide funds.  We may repay any loans, costs of services and
advancements with cash, if available, or we may convert them into common
stock.

     Our management intends to actively pursue business opportunities during
the next twelve months.  Based on current economic and regulatory conditions,
management believes that it is possible, if not probable, for a company like
ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company.  The opportunity arises principally because of
the high legal and accounting fees and the length of time associated with the
process of "going public."  However, should any of these conditions change, it
is very possible that there would be little or no economic value for anyone
taking over control of Skinovation. In addition, we have not made a formal
study of the economic potential of any business.  At the date of this filing,
we have not identified any assets or business opportunities for acquisition.

     All risks inherent in new and inexperienced enterprises are inherent in
our business.  Potential investors must recognize that because of limited
capital available for investigation and management's limited experience in
business analysis we may not discover or adequately evaluate adverse facts
about any business opportunity to be acquired.  Also, we intend to concentrate
our acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.

     It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

     Should a merger or acquisition prove unsuccessful, it is possible that we
may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.


                                8

<PAGE>

ITEM 3: CONTROLS AND PROCEDURES

     Our President, who acts in the capacity of principal executive officer
and principal financial officer, has reevaluated the effectiveness of our
disclosure controls and procedures as of the end of the period covered by this
report and determined that there continued to be no significant deficiencies
in these procedures.  Also, there were no changes made or corrective actions
to be taken related to our internal control over financial reporting.


                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

Part II Exhibits

3.1     Articles of Incorporation as amended  (Incorporated by reference to
        exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)
3.2     Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
        Form-SB, filed July 11, 2000)
31.1    Principal Executive Officer Certification
31.2    Principal Financial Officer Certification
32.1    Section 1350 Certification

Reports on Form 8-K

     None.


                            SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


                                   Skinovation Pharmaceutical Incorporated

                                    /s/ John W. Peters
Date: October 28, 2003          By: ____________________________________
                                    John W. Peters
                                    President, Principal Executive and
                                    Financial Officer, and Director


                                9